



HER2 Positivity in Gastric Cancer; a Review of 23 Cases

Salimi Amrollah, Besharati Mahsa, etekhari shahin

Surgery Department, shahid beheshti Hospital, Qom University of Medical Sciences, Qom, IRAN

Abstract

Introduction: The aim of the study is to ascertain HER2 positivity in gastric cancer witch operated in our center and to evaluate its correlation with staging and response to treatment.

Method: Twenty-three patients with gastric adeno carcinoma that operated from august 2013 to march 2016 were selected for study. Staging and clinical finding evaluated and compared with result of HER2 positivity according to immune histochemistry.

Results: All the patients were above the 26-year-old ranged from 26 to 76 with average of 58 years. Seventeen patients were male and ten were female. The entire patents were stage two and above with lymph node involvement. For eighteen patient's gastrectomy was performed; but according to extention of the tumor at the time of diagnosis nine patients were non operable, furthermore only biopsy was taken and chemotherapy and radiotherapy were done. In ten patients her2 were positive by immunohistochemistry that applied on the paraffin block. HER2 positivity were recorded according to staging, Sex, Lymph node involvement, Metastasis and age.

Conclusion: HER2 overexpression is increasingly recognized as a frequent molecular abnormality, driven as breast cancer by gene amplification. There is mounting evidence of the role of HER2 overexpression in patients with gastric cancer, and it has been solidly correlated to poor outcomes and a more aggressive disease. Additionally, preclinical data are showing significant antitumor efficacy of anti-HER2 therapies.

Key Words: HER2. Gastric Tumor. Adeno Carcinoma, Trastuzumab